| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.032 | 0.4 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.065 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |